MKC vs. MRNA

Last updated Jun 13, 2026

MKC (McCormick & Company, Incorporated) and MRNA (Moderna, Inc.) are both stocks. MKC operates in Packaged Foods (Consumer Defensive), while MRNA operates in Biotechnology (Healthcare). Over the past 5 years, MKC returned -9.29%/yr vs -25.59%/yr for MRNA. At a 0.10 correlation, their price movements are largely independent.

Performance

MKC vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in McCormick & Company, Incorporated (MKC) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MKC achieves a -27.49% return, which is significantly lower than MRNA's 69.24% return.

MKC

• 1D: -0.57%
• 1M: 5.61%
• YTD: -27.49%
• 6M: -25.55%
• 1Y: -31.93%
• 3Y*: -16.44%
• 5Y*: -9.29%
• 10Y*: 1.82%

MRNA

• 1D: 0.54%
• 1M: 1.77%
• YTD: 69.24%
• 6M: 69.42%
• 1Y: 87.14%
• 3Y*: -26.94%
• 5Y*: -25.59%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

MKC vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
MKC McCormick & Company, Incorporated	-27.49%	-8.33%	13.97%	-15.68%	-12.65%	2.67%	14.70%	23.65%	-7.80%
MRNA Moderna, Inc.	69.24%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	28.09%	-30.59%

Correlation

The correlation between MKC and MRNA is 0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.02
Correlation (3Y) Calculated over the trailing 3-year period	0.10
Correlation (5Y) Calculated over the trailing 5-year period	0.10
Correlation (All Time) Calculated using the full available price history since Dec 7, 2018	0.10

Fundamentals

Market Cap MKC : $13.19B MRNA : $19.71B
EPS MKC : $6.10 MRNA : -$8.16
PS Ratio MKC : 1.85 MRNA : 8.78
PB Ratio MKC : 1.89 MRNA : 2.66
Total Revenue (TTM) MKC : $7.11B MRNA : $2.23B
Gross Profit (TTM) MKC : $2.70B MRNA : -$309.00M
EBITDA (TTM) MKC : $1.22B MRNA : -$3.02B

Return for Risk

MKC vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MKC

MKC Risk / Return Rank: 5
MKC Sharpe Ratio Rank: 2
MKC Sortino Ratio Rank: 4
MKC Omega Ratio Rank: 6
MKC Calmar Ratio Rank: 9
MKC Martin Ratio Rank: 3

MRNA

MRNA Risk / Return Rank: 78
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 79
MRNA Omega Ratio Rank: 75
MRNA Calmar Ratio Rank: 79
MRNA Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MKC vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for McCormick & Company, Incorporated (MKC) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	MKC	MRNA	Difference
Sharpe ratio: Return per unit of total volatility	-1.20	1.28	-2.48
Sortino ratio: Return per unit of downside risk	-1.70	2.13	-3.83
Omega ratio: Gain probability vs. loss probability	0.80	1.24	-0.44
Calmar ratio: Return relative to maximum drawdown	-0.85	2.34	-3.19
Martin ratio: Return relative to average drawdown	-1.69	4.59	-6.27

MKC vs. MRNA - Sharpe Ratio Comparison

The current MKC Sharpe Ratio is -1.20, which is lower than the MRNA Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of MKC and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

MKC vs. MRNA - Drawdown Comparison

The maximum MKC drawdown since its inception was -52.02%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for MKC and MRNA.

Drawdown Indicators

	MKC	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-52.02%	-95.38%	+43.36%
Max Drawdown (1Y) Largest decline over 1 year	-39.50%	-35.51%	-3.99%
Max Drawdown (3Y) Largest decline over 3 years	-47.65%	-86.58%	+38.93%
Max Drawdown (5Y) Largest decline over 5 years	-52.02%	-95.38%	+43.36%
Max Drawdown (10Y) Largest decline over 10 years	-52.02%	—	—
Current Drawdown Current decline from peak	-48.49%	-89.70%	+41.21%
Average Drawdown Average peak-to-trough decline	-11.03%	-57.06%	+46.03%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.92%	18.06%	+1.86%

Volatility

MKC vs. MRNA - Volatility Comparison

The current volatility for McCormick & Company, Incorporated (MKC) is 6.12%, while Moderna, Inc. (MRNA) has a volatility of 17.56%. This indicates that MKC experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MKC	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.12%	17.56%	-11.44%
Volatility (6M) Calculated over the trailing 6-month period	23.28%	48.82%	-25.54%
Volatility (1Y) Calculated over the trailing 1-year period	28.06%	64.75%	-36.69%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	24.34%	66.49%	-42.15%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	24.17%	72.15%	-47.98%

Dividends

MKC vs. MRNA - Dividend Comparison

MKC's dividend yield for the trailing twelve months is around 3.80%, while MRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MKC McCormick & Company, Incorporated	3.80%	2.69%	2.24%	2.32%	1.81%	1.44%	1.68%	1.37%	1.53%	1.89%	1.89%	1.91%
MRNA Moderna, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both MKC and MRNA in my portfolio?

MKC and MRNA have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MKC or MRNA?

MRNA has higher volatility (17.56%) compared to MKC (6.12%). In terms of maximum drawdown, MKC dropped -52.02% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.28 vs -1.20), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.